FOLOTYN is the first and just drug authorized by the FDA for the treatment of patients with relapsed or refractory PTCL. This indication is based on overall response rate. Clinical advantage such as for example improvement in progression free of charge survival or overall survival has not been demonstrated.. Allos Therapeutics reports new evaluation of PROPEL trial data of FOLOTYN in sufferers with refractory PTCL Allos Therapeutics, Inc. The objective of this retrospective subgroup analysis was to measure the activity and safety of single-agent FOLOTYN in patients enrolled in PROPEL who were diagnosed with histologically verified relapsed or refractory transformed mycosis fungoides , which can be an aggressive and difficult to treat T-cell lymphoma.D., professor of medication and of dermatology, Yale School of Medicine.Their lives – a 10-to-14-year period – will end up being tracked for genetic usually, nutritional and environmental dangers to help scientists and veterinarians find ways to prevent canine cancer, considered the No widely. 1 cause of death in older dogs, said Dr. Rodney Web page. The Golden Retriever Life time Study shall be the biggest and longest dog study ever conducted, said Page, the study’s principal investigator, a professor of veterinary oncology and the director of the Flint Animal Cancer Middle at Colorado State University.